explore -WSS

explore

author：fashion 2025-09-28 23:47:12 - browse：524

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Big Tobacco's 'harm reduction': Is it for real, or a sham?

WSS

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

For longer

When prostate cancer spreads, where it goes matters

Cue Health, Covid

Glen Campbell's doctor discusses his public struggle with Alzheimer's

entertainment

explore

knowledge

In age of alternative facts, a scholarly course on calling out crap

HIV vaccine remains elusive. Immunologists keep trying new ideas

Heart attack and stroke risk calculators need revising

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Psychedelics group wrestles with new pharma identity

When prostate cancer spreads, where it goes matters

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

H5N1 virus can be tracked in retail milk, scientists say

Medical records are filled with copy

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Wikipedia

Digital health: a case of mistaken identity

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Data integrity in scientific journals requires "effort" by publishers, institutions

Cue Health, Covid

Readers respond to H5N1 and livestock movements, and more

Liver decline slowed by off

leisure time

knowledge

entertainment

focus